In Q1 2024, Cormorant Asset Management held 45 positions worth $1.9B. They initiated 12 new positions and exited 34. Their largest holding was MLTX ($426.7M). Portfolio value grew +18.1% versus the prior quarter.
Frequently asked questions
What stocks did Cormorant Asset Management own in Q1 2024?
Cormorant Asset Management held 45 biotech stocks in their 13F portfolio in Q1 2024. Their top positions include MLTX, EYPT, ACLX, BBIO, PRAX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Cormorant Asset Management's portfolio worth in Q1 2024?
Cormorant Asset Management's tracked biotech portfolio was worth $1.9B across 45 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
What did Cormorant Asset Management buy in Q1 2024?
Cormorant Asset Management initiated 12 new positions in Q1 2024, including CRBP, NAMSW, CGON, HLXC, JANX and 7 more. They also increased 10 existing positions.
What did Cormorant Asset Management sell in Q1 2024?
Cormorant Asset Management fully exited 34 positions in Q1 2024, including XFOR, VKTX, TNGX, PYXS, RXDX and 29 more. They also trimmed 7 existing positions.
Is Cormorant Asset Management a biotech fund?
Healthcare-focused crossover fund that invests from late-stage private through public markets. Known for concentrated, high-conviction positions in clinical and commercial-stage biotech companies with strong scientific differentiation.
Want AI analysis, insider signals, and catalyst overlays for Cormorant Asset Management?
View latest Cormorant Asset Management portfolio →